Celebrate High-Loween with Shroom Garden - 20% off all THC EDIBLES AND SHAtTER!
Celebrate High-Loween with Shroom Garden - 20% off all THC EDIBLES AND SHAtTER!
If you have been following the psychedelic research space, you have probably noticed something shifting. Psilocybin, the psychoactive compound in magic mushrooms, has moved from the fringes of counterculture into the pages of JAMA Psychiatry, Nature Medicine, and Health Canada–authorized clinical trials. But what does the 2026 evidence actually say? And what does it mean for Canadians exploring therapeutic options?
This is not a sales pitch. It is a plain-language breakdown of the most significant clinical trials published this year, what they found, what they did not find, and how researchers are studying the therapeutic potential of different psilocybin-containing mushrooms. Whether you are a patient, a curious beginner, or someone who has been researching psilocybin for years, this is what the science currently supports.
The largest recent randomized clinical trial of psilocybin for treatment-resistant depression (TRD) was published in JAMA Psychiatry on March 18, 2026. The EPISODE trial investigated psilocybin 25 mg with adjunct psychotherapy in 144 participants with treatment-resistant major depression. This was a triple-blinded trial with an active placebo and four dosing regimens, one of the most methodologically rigorous designs in psychedelic research to date.
The results were nuanced. Response rates on the primary endpoint were 17.0% in the 25 mg group, 12.5% in the 5 mg group, and 10.6% in the nicotinamide (active placebo) group. Psilocybin was associated with a clinically meaningful reduction in depressive symptoms, but the findings did not show a significant effect on the primary outcome. In plain terms: the trial showed promise, but it also showed that psilocybin is not a guaranteed cure, and the placebo response in psychedelic trials is substantial.
The PSI-TNT trial at the Centre for Addiction and Mental Health (CAMH) in Toronto is evaluating the role of psilocybin monitors in psilocybin therapy for treatment-resistant depression. The trial uses 25 mg psilocybin and is a pilot randomized clinical trial. This is significant because it is one of the few Canadian-led trials examining not just whether psilocybin works, but how the therapeutic context, including the presence of trained monitors, influences outcomes.
In September 2026, Optimi Health completed production of a batch of 5 mg naturally derived psilocybin capsules for a Health Canada–authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. The trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027.
What makes this trial notable is that the psilocybin is manufactured end-to-end at Optimi’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The same batch is also being supplied to licensed clinics in Australia, where 5 mg psilocybin capsules are prescribed to patients with treatment-resistant depression under the Therapeutic Goods Administration’s Authorised Prescriber Scheme. This is the first time a single batch of psilocybin has served both a Canadian clinical trial and a commercial medical supply chain.
The PSYCHED-PAL trial, conducted at two academic hospitals in Ottawa, is the first clinical study of microdose psilocybin for psychological distress in palliative care. The trial used a 3-week oral psilocybin intervention: 1 mg daily in week 1, 2 mg in week 2, and 3 mg in week 3.
Of the 13 participants who completed the intervention, 62% reported more than 50% improvement in Hamilton Depression Rating Scale scores, and 54% reported more than 50% improvement in anxiety and depression measures. There were no serious adverse events reported. The researchers concluded that microdose psilocybin is “safe, feasible and potentially efficacious” for psychological distress in people with advanced illness.
One of the most common questions from people exploring psilocybin for therapeutic purposes is simple: does the strain matter?
The clinical trials use synthetic psilocybin or standardized natural psilocybin capsules, not dried mushrooms purchased from a dispensary. The EPISODE trial used 25 mg psilocybin. The Optimi trial uses 5 mg capsules. The PSYCHED-PAL trial used 1–3 mg microdoses. In every case, the dose is precisely measured and standardized.
This does not mean that strain differences are irrelevant. It means that the clinical evidence is built on standardized doses, not on the variability that comes with dried mushrooms. For researchers, that standardization is essential. For individuals exploring therapeutic use, it means that precision matters, which is why many people who are interested in therapeutic exploration gravitate toward pre-measured formats.
This is where edibles and precision-dosed products come in. Shroom Garden carries a range of psilocybin edibles including Adventures Chocolate and Truphoria Gummies, which offer consistent dosing without the need to measure dried mushrooms. For those who prefer dried mushrooms, the shrooms category includes strains like Golden Teacher, Golden Emperor, and Albino Penis Envy, each with its own potency profile.
Any honest conversation about psilocybin has to include side effects. The clinical trial data is clear: psilocybin is not without risks, but the acute side effects are typically manageable.
A systematic review of 42 published studies found that the most common adverse events were headache, elevated blood pressure, and nausea. A separate meta-analysis found that therapeutic doses of psilocybin produce “tolerable acute adverse effects that typically resolved within 24 to 48 hours”. Anxiety during dosing sessions was also reported, often resolving as the session progressed.
What the trials do not show is frequent serious adverse events. Severe side effects have rarely been seen in clinical trials. However, hallucinogen persisting perception disorder, a condition where perceptual disturbances recur after the acute effects have stopped, has been reported in recreational users, though its incidence after psilocybin use is unknown.
For anyone considering therapeutic use, the takeaway is straightforward: the risks are real but manageable in supervised settings. Self-administering high doses without preparation or support is a different matter entirely.
The Canada-wide legal pathway for patients is the Special Access Program (SAP), which allows physicians to request psilocybin for serious or life-threatening conditions where conventional treatments have failed.
The regulatory landscape is shifting, though. Bill C-286, introduced in June 2026 by Conservative MP Corey Tochor, would amend the CDSA and Food and Drugs Act to allow psilocin and psilocybin to be used for medical treatment under the Narcotic Control Regulations, effectively legalizing medical psilocybin and allowing doctors to prescribe it without submitting each request to Health Canada. The bill is currently in the legislative process.
Shroom Garden is a Canada-wide online dispensary offering magic mushrooms and psilocybin edibles. The products discussed in this article are not medicines and are not intended to diagnose, treat, or cure any condition. If you are struggling with depression or any other mental health condition, speak with a healthcare provider about all available options, including clinical trials and the Special Access Program.
For those who are researching psilocybin from an educational perspective, Shroom Garden’s website also carries merch, cannabis, and vapes categories. You can follow the brand on Instagram and read customer reviews on Trustpilot.
What does the EPISODE trial actually show about psilocybin for depression?
The EPISODE trial (JAMA Psychiatry, March 2026) found that psilocybin 25 mg with psychotherapy was associated with clinically meaningful symptom reduction in treatment-resistant depression, but did not meet statistical significance on the primary endpoint. Response rates were 17.0% for 25 mg versus 10.6% for active placebo.
What are the most common side effects of psilocybin in clinical trials?
Headache, elevated blood pressure, nausea, and anxiety during dosing sessions are the most commonly reported adverse events. These typically resolve within 24–48 hours. Serious adverse events are rare in supervised clinical settings.
How does microdose psilocybin differ from a full therapeutic dose?
Microdoses (1–3 mg) are sub-psychedelic and do not typically produce hallucinogenic effects. The PSYCHED-PAL trial used 1–3 mg daily over three weeks. Full therapeutic doses in depression trials use 25 mg. The clinical evidence for microdosing is still early-stage compared to full-dose research.
Where can I buy magic mushrooms online in Canada?
Shroom Garden offers psilocybin edibles and dried mushrooms with Canada-wide shipping. Browse the full shrooms collection for strain options including Golden Teacher, Golden Emperor, and Albino Penis Envy.
What types of psilocybin-infused products are available for purchase?
Shroom Garden carries precision-dosed chocolate and gummies under the edibles category, alongside dried mushroom strains such as Golden Mammoth, Ecuadorian, Cambodian, and Bulk Grounded Shrooms for those who prefer to measure their own doses.
What are you looking for?
